OKL-1111
Anticoagulant reversal for Hemorrhagic Stroke / Intracranial Hemorrhage (ICH)
Pre-clinicalActive Development
Key Facts
Indication
Anticoagulant reversal for Hemorrhagic Stroke / Intracranial Hemorrhage (ICH)
Phase
Pre-clinical
Status
Active Development
Company
About Alveron Pharma
Alveron Pharma is a private, pre-clinical stage biotech focused on revolutionizing the treatment of life-threatening bleeds caused by anticoagulants. Its lead candidate, OKL-1111, is a synthetic, universal reversal agent designed for rapid administration in emergencies like hemorrhagic stroke, potentially cutting treatment delays from over an hour to minutes. The company is backed by European venture capital and leverages a management team with deep experience in coagulation therapeutics and drug development.
View full company profile